Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buhl, R.
Right arrow Articles by Farmer, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buhl, R.
Right arrow Articles by Farmer, S. G.
The Proceedings of the American Thoracic Society 1:136-142 (2004)
© 2004 The American Thoracic Society

Current and Future Pharmacologic Therapy of Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma

Roland Buhl and Stephen G. Farmer

Pulmonary Department, Mainz University Hospital, Mainz, Germany; and AstraZeneca Pharmaceuticals, Wilmington, Delaware

Correspondence and requests for reprints should be addressed to Roland Buhl, Pulmonary Department, Mainz University Hospital, Langenbeckstrasse 1, D-55131 Mainz, Germany. E-mail: r.buhl{at}3-med.klinik.uni-mainz.de

Exacerbations are an important cause of the morbidity and mortality associated with asthma and chronic obstructive pulmonary disease. Newer therapies include long-acting ß2-agonists, which are more effective than short-acting bronchodilators. Inhaled corticosteroids and, in asthma, leukotriene receptor antagonists may have roles in the early phase of exacerbation as an alternative to or added to oral prednisolone. In the future, combinations of long-acting ß2-agonists and anticholinergic bronchodilators may offer additive clinical benefits. However, although the treatment and prevention of exacerbations of chronic obstructive pulmonary disease and asthma have been improved by using combinations of known therapies, further research addressing the underlying etiology as well as molecular and pathophysiologic mechanisms of exacerbation is needed to better target novel therapies to the appropriate patient populations and to develop new therapeutic strategies.

Key Words: chronic obstructive pulmonary disease • asthma • exacerbation • therapy




This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Ogawa, A. L. Firth, W. Yao, L. J. Rubin, and J. X.-J. Yuan
Prednisolone inhibits PDGF-induced nuclear translocation of NF-{kappa}B in human pulmonary artery smooth muscle cells
Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L648 - L657.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
R. Buhl and S. G. Farmer
Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Thoracic Society. 		 
ATS Quiz on Sleep Study Tracings